After her internship, she did a PhD thesis at the Institute of Cancer Research, London, as part of the team of Alan Ashworth, focusing on DNA repair and synthetic lethality.
She completed her post-doctoral fellowship in Paris and spent 18 months at the Royal Marsden Hospital in London in Professor Stanley Kaye's drug development unit.
[1][2] She defended her dissertation, titled Synthetic lethality and functional study of DNA repair defects in ERCC1-deficient non-small-cell lung cancer, in December 2016.
[2] Her research activity focuses on chromatin remodeling and its interaction with DNA damage repair and immune modulation in solid tumor cancer models.
Her research interests include DNA repair and chromatin remodeling, synthetic lethality, sarcoma, drug development, predictive biomarkers and novel targets.